$TEVA

Teva Pharmaceutical beats Q1 earnings expectations and announces $700M Emalex acquisition plus share buyback, signaling confidence in specialty drug strategy and cost-cutting targets.

Teva acquires Emalex Biosciences for $700M upfront plus $200M in milestones for first-in-class Tourette syndrome therapy, closing by Q3 2026.

Global dermatomycoses market expected to grow significantly through 2035, driven by rising fungal infections and immunocompromised populations. Key players include Novartis, Bayer, and Sun Pharma.

Biolojic Design presents preclinical data for BD200, a dual-target cancer drug showing superior efficacy against resistant tumors. Clinical trials expected in H2 2026.

Teva launches Home Ground™ Schizophrenia Community, a free online platform addressing social isolation affecting 75% of psychotic disorder patients through peer support and digital tools.

Teva Pharmaceuticals and Direct Relief fund mental health expansion at 11 free clinics across Alabama, Mississippi, and Texas, reaching 57,000 patients.

Crohn's Disease drug market projected to grow 45% to $13.8B by 2032, driven by eight new therapies with novel mechanisms of action reshaping competition.

Viatris trades 17% below peers despite 13.5% FCF yield and $2.2B annual cash generation. Growth catalysts and cost-savings program launching 2026 suggest significant upside.

Teva gains FDA approval for denosumab biosimilar PONLIMSI and achieves dual filing acceptance for omalizumab candidate, bolstering its biosimilars portfolio.

Teva wins FDA approval for PONLIMSI biosimilar and dual regulatory filing acceptance for omalizumab biosimilar, advancing its 'Pivot to Growth' strategy.

Teva gains FDA approval for PONLIMSI denosumab biosimilar and dual regulatory acceptance for omalizumab candidate, advancing biosimilar growth strategy.

BIO-Europe Spring 2026 in Lisbon expects 3,700+ attendees, 20,000+ meetings, and robust partnering activity as global biopharma industry seeks strategic deals and investment opportunities.

Billionaire Druckenmiller slashed positions in $TSM and $TEVA after doubling, pivoting $301M into financial sector ETF as second-largest fund holding.

Teva and Blackstone Life Sciences announce $400 million four-year funding agreement to develop duvakitug for inflammatory bowel disease, supporting Teva's specialty pharma pivot.

Teva Pharmaceutical faces margin compression in generic drugs, pivoting toward complex generics and original drug development. Limited financial flexibility creates elevated execution risk.

Teva's once-monthly schizophrenia injection TEV-749 advances toward FDA approval, aiming to improve patient medication compliance and reduce healthcare burden compared to daily oral treatments.

FDA accepts Teva's application for monthly olanzapine injection treating schizophrenia. The formulation eliminates post-injection monitoring requirements while maintaining efficacy.

Teva and Sanofi report positive Phase 3 results for duvakitug IBD treatment, with over 55% of patients meeting efficacy endpoints. Stock rises 2.85%.

Sanofi and Teva report duvakitug maintains efficacy in IBD maintenance trial, with remission rates of 47-58% in ulcerative colitis. Drug advances to Phase III development.

Sanofi and Teva's duvakitug showed sustained efficacy treating ulcerative colitis and Crohn's disease in a Phase 2b trial, supporting advancement to Phase 3 development.